Skip to main content

Bipartisan Senators Introduce Marijuana And CBD Research Bill

A bipartisan group of lawmakers introduced a bill on Thursday that’s meant to promote federally authorized research into marijuana and its derivatives like CBD. It was one of several pieces of new congressional cannabis legislation to be filed on the same day.

Sens. Dianne Feinstein (D-CA), Brian Schatz (D-HI) and Chuck Grassley (R-IA) are leading the bill, which would streamline the application process for researchers interested in studying the plant, encourage the development of Food and Drug Administration (FDA)-approved drugs derived from marijuana and clarify that doctors can discuss the benefits of cannabis with patients.

It would also require the U.S. Department of Health and Human Services (HHS) to submit a report on the health benefits and risks of marijuana, as well one on barriers to cannabis research and how to overcome those obstacles.

The bill, at 22 pages, covers a lot of ground, and that’s partly because it combines legislation previously filed by the sponsors.

“Many parents have had success treating their children with CBD oil, particularly for intractable epilepsy, but there are still too many unknowns when it comes to the medical use of marijuana and its compounds,” Feinstein said in a press release. “Current regulations make medical marijuana research difficult and stifles the development of new treatments.

“Our combined bill streamlines the research process and paves the way for marijuana-derived medications that are FDA-approved to keep consumers safe,” she said.

Grassley added that research “is necessary to determine the potential medical value of cannabidiol, and wherever possible, the government should help facilitate the scientific research needed to give these parents the answers they need.”

The first section of the bill concerns the application process for institutions seeking federal authorization to research marijuana. The U.S. attorney general would be given a 60-day deadline to either approve a given application or request supplemental information from the applicant. It would also create an expedited pathway for researchers who request larger quantities of Schedule I drugs.

Another provision addresses applications to become a federally authorized cannabis manufacturer for research purposes. Currently, only one such facility exists nationwide, at the University of Mississippi. The legislation would give the Justice Department a similar 60-day deadline to approve such applications or ask for more information.

The second major section of the bill is about FDA approval of marijuana-derived drugs. One way to encourage such developments is through allowing “accredited medical and osteopathic schools, practitioners, research institutions, and manufacturers with a Schedule I registration” to cultivate their own cannabis for research purposes.

The Drug Enforcement Administration would get a mandate to approve applications to be manufacturers of marijuana-derived, FDA-approved drugs under the bill. Manufacturers would also be allowed to import cannabis materials to facilitate research into the plant’s therapeutic potential.

“The medical community agrees that we need more research to learn about marijuana’s potential health benefits, but our federal laws today are standing in the way of that inquiry,” Schatz said. “Our bill will remove excessive barriers that make it difficult for researchers to study the effectiveness and safety of marijuana, and hopefully, give patients more treatment options.”

There’s another section of the legislation on doctors discussing marijuana with patients. A summary of the bill states that it would allow physicians to talk about cannabis derivatives like CBD with children if their legal guardian consents and also generally allows them to “discuss the potential harms and benefits of both marihuana and its derivatives with adult patients.” Federal courts have already ruled that discussing and recommending medical cannabis is a right guaranteed by the First Amendment, though, so it’s not clear how it would have an impact beyond providing legislative clarification and assurances.

Finally, a fourth section would require HHS to look at the health benefits and risks of marijuana as well as policies that are inhibiting research into cannabis that’s grown in legal states and provide recommendations on overcoming those barriers.

“In addition, it encourages the federal government to facilitate more medical research on marihuana and its components, including the potential therapeutic effects on serious medical conditions,” a summary of the legislation states.

In a statement for the Congressional Record, Feinstein said that “anecdotal evidence suggests that marijuana and its derivatives, like cannabidiol, commonly known as CBD, may be helpful in treating serious medical conditions.”

“However, anecdotal evidence alone cannot be the basis for developing new medications. Rather, medication development must be based on science,” she said. “Unfortunately, marijuana research is subject to burdensome regulations which may unintentionally inhibit research and medication development.”

“I have heard from many parents who have turned to CBD as a last resort to treat their children who have intractable epilepsy… I have heard similar stories from people who use marijuana to treat various other medical conditions.

“But a common concern echoed in many of these conversations is that there is a lack of understanding about the proper delivery mechanism, dosing, or potential interactions that CBD or marijuana may have with other medications. Some also worry because these products aren’t well regulated or factory sealed, and often are labeled incorrectly. Without additional research, our ability to adequately address these concerns is limited and uninformed…

“I firmly believe that we should reduce the regulatory barriers associated with researching marijuana and CBD. If and when science shows that these substances are effective in treating serious medical illnesses, we should enable products to be brought to the market with FDA approval.”

The bill’s original cosponsors include Sens. Dick Durbin (D-IL), Thom Tillis (R-NC), Tim Kaine (D-VA), Joni Ernst (R-IA), Kevin Cramer (R-ND) and presidential candidate Amy Klobuchar (D-MN).

The proposal has been endorsed by mainstream medical organizations like American Academy of Pediatrics, American Medical Association, American Psychological Association and American Society of Addiction Medicine, as well as pro-legalization groups such as Americans for Safe Access, Multidisciplinary Association of Psychedelic Studies and NORML.

For no apparent reason, Thursday was especially active for congressional marijuana legislation. Rep. Earl Blumenauer (D-OR) and Sen. Ron Wyden (D-OR) filed bills that would allow for the interstate commerce of cannabis products, and Sen. Cory Booker (D-NJ), another presidential candidate, introduced a proposal to protections immigrants from being deported for marijuana. Legislation concerning cannabis businesses’ access to Small Business Administration programs was also filed.

Read the text of the new marijuana and CBD research bill below:

CBD and Marijuana Research Expansion Act by Marijuana Moment on Scribd

Original Article Source: https://www.marijuanamoment.net/bipartisan-senators-introduce-marijuana-and-cbd-research-bill/

Comments

Post a Comment

Popular posts from this blog

New York City Adds More Exceptions To Pre-Employment Marijuana Testing Ban

An ambitious campaign to decriminalize psychedelics in Washington, D.C., is one step closer to placing their measure on the November ballot with the formal submission of tens of thousands of voter signatures. Organizers have been scrambling for weeks to collect enough signatures from D.C. voters by Monday’s deadline amid historically difficult circumstances: a global pandemic, months of stay-at-home orders and protests over racism and police violence that filled the streets of the nation’s capital. But with the help of innovative signature-gathering techniques and allies flown in from across the country, advocates said they had successfully submitted upwards of 35,000 signatures—more than enough to qualify the initiative. If approved by voters, Initiative 81 would make enforcement of laws against plant- and fungus-based psychedelics among the “lowest law enforcement priorities” for the Metropolitan Police Department. It would not, however, legalize or reduce penalties for the subs
Post a Comment
Read more

Charlotte Figi The Girl Who Inspired A CBD Movement Has Died At Age 13

Charlotte had recently been hospitalized due to pneumonia, breathing problems and seizures. She was treated as a likely case of Covid-19, her mother, Paige Figi, said Wednesday, although she tested negative for the virus. “Charlotte is no longer suffering. She is seizure-free forever,” a family friend wrote on Paige Figi’s Facebook page, announcing Charlotte’s death. “Thank you so much for all of your love.” Charlotte became a symbol of the possibilities of CBD after CNN Chief Medical Correspondent Dr. Sanjay Gupta told her story in the documentary “Weed.” In the film, Charlotte was shown to be a playful child who was overcome by horrific seizures, which were quelled with Charlotte’s Web, a marijuana strain named in her honor. Charlotte had Dravet syndrome, a rare form of epilepsy which was not controlled by medication. The Stanley brothers, marijuana growers in Colorado, were crossbreeding a strain of marijuana high in CBD and low in THC, its psychoactive ingredient. After Charlo
Post a Comment
Read more

Virginia CBD Program Criticized As Multistate Medical Cannabis Operators Gain Edge

Seven companies are challenging a CBD licensing process in Virginia that resulted in multistate medical marijuana operators getting a majority of available licenses. The appeals called the process “wildly prejudicial.” Out of 51 applicants for five vertically integrated CBD and THC-A licenses, multistate operators received three, a situation that spurred the appeals, The Virginian-Pilot reported. Applicants filing the appeals complained the closed-meeting review process lacked fairness and transparency. One consultant to an applicant said the selections felt “predetermined.” The Virginia Board of Pharmacy reportedly sent information to the applicants in December explaining its selections, but some applicants weren’t satisfied. A board spokeswoman wrote in an email to the Pilot that the board “does not comment on pending litigation.” The five winning applicants , called “pharmaceutical processors,” have a year from winning the licenses to become operational. The multistate
Post a Comment
Read more